Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.).
Authors
- Maria J. Merino
- Eric A. Singer (ORCID: https://orcid.org/0000-0003-3991-0696)
- Sandeep Gurram (ORCID: https://orcid.org/0000-0002-6405-9269)
- Edward W. Cowen (ORCID: https://orcid.org/0000-0003-1918-4324)
- Mark W. Ball (ORCID: https://orcid.org/0000-0003-1780-2627)
- Heidi H. Kong (ORCID: https://orcid.org/0000-0003-4424-064X)
- Munjid Al Harthy
- Cathy D. Vocke (ORCID: https://orcid.org/0000-0002-9256-7607)
- Joanna H. Shih (ORCID: https://orcid.org/0000-0001-9815-3651)
- Erin B. Purcell (ORCID: https://orcid.org/0000-0002-8736-0433)
- Lisa Mac
- Ashkan A. Malayeri (ORCID: https://orcid.org/0000-0002-4442-7343)
- W. Marston Linehan (ORCID: https://orcid.org/0000-0001-7983-3109)
- Christopher J. Ricketts (ORCID: https://orcid.org/0000-0003-4814-7207)
- Abhinav Sidana (ORCID: https://orcid.org/0000-0002-3197-7215)
- Ramaprasad Srinivasan
- Julia C. Friend
Institutions
- National Institutes of Health (US)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1056/nejmoa2200900
- Citations
- 22
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 33.40
Funders
- National Cancer Institute